Such results implied that diverse phenylalkylamines, functioning as CaSR negative allosteric modulators (NAMs or calcilytics; e.g., NPS 89636 and NPS 2143) able to move the CaSR response curve to alterations of [Ca2+]e [22,24] may be prospective AD medicaments. This evidence concerns the gene CASR and Alzheimer disease.